Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vinorelbine vs Gemcitabine + Vinorelbine in Advanced Breast Cancer
NCT00128310Phase 3Completed
- Sponsor
- GEICAM
- Start
- Jan 2001
- Primary completion
- Aug 2006
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of gemcitabine in breast cancer (2 arms), sponsored by GEICAM. Primary endpoint: Progression-free survival at 1 year. Started Jan 2001; status: completed.
02
Drugs
gemcitabine
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00128310.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00128310.